Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Enliven Therapeutics, Inc. | Director, 10%+ Owner | Common Stock | 7.66M | $170M | $22.14 | May 16, 2024 | Indirect |
Verona Pharma plc | Director | Ordinary Shares | 3.78M | $75.6M | $20.00 | May 15, 2023 | Indirect |
Turnstone Biologics Corp. | Director, 10%+ Owner | Common Stock | 3.1M | Jul 20, 2023 | Indirect | ||
Enliven Therapeutics, Inc. | Director, 10%+ Owner | Stock Option (right to buy) | 23.4K | Feb 13, 2024 | Direct | ||
Turnstone Biologics Corp. | Director, 10%+ Owner | Stock Option (Right to Buy) | 12.8K | Jun 3, 2024 | Direct | ||
Turnstone Biologics Corp. | Director, 10%+ Owner | Series B-1 Preferred Stock | 0 | Jul 20, 2023 | Indirect | ||
Turnstone Biologics Corp. | Director, 10%+ Owner | Series B-2 Preferred Stock | 0 | Jul 20, 2023 | Indirect | ||
Turnstone Biologics Corp. | Director, 10%+ Owner | Series C Preferred Stock | 0 | Jul 20, 2023 | Indirect | ||
Turnstone Biologics Corp. | Director, 10%+ Owner | Series D Preferred Stock | 0 | Jul 20, 2023 | Indirect |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
TSBX | Turnstone Biologics Corp. | Jun 3, 2024 | 1 | $0 | 4 | Jul 2, 2024 | Director, 10%+ Owner |
ELVN | Enliven Therapeutics, Inc. | May 16, 2024 | 2 | -$22.9M | 4 | May 20, 2024 | Director, 10%+ Owner |
ELVN | Enliven Therapeutics, Inc. | Feb 13, 2024 | 1 | $0 | 4/A | Feb 20, 2024 | Director, 10%+ Owner |
ELVN | Enliven Therapeutics, Inc. | Feb 13, 2024 | 1 | $0 | 4 | Feb 15, 2024 | Director, 10%+ Owner |
TSBX | Turnstone Biologics Corp. | Oct 16, 2023 | 1 | $0 | 4 | Oct 17, 2023 | Director, 10%+ Owner |
TSBX | Turnstone Biologics Corp. | Jul 20, 2023 | 6 | $5M | 4 | Jul 24, 2023 | Director, 10%+ Owner |
TSBX | Turnstone Biologics Corp. | Jul 20, 2023 | 0 | $0 | 3 | Jul 20, 2023 | Director, 10%+ Owner |
ELVN | Enliven Therapeutics, Inc. | May 17, 2023 | 2 | $9.1K | 4 | May 19, 2023 | Director, 10%+ Owner |
VRNA | Verona Pharma plc | May 11, 2023 | 4 | -$9.94M | 4 | May 15, 2023 | Director |
VRNA | Verona Pharma plc | Apr 28, 2023 | 1 | $0 | 4 | Apr 28, 2023 | Director |
ELVN | Enliven Therapeutics, Inc. | Feb 23, 2023 | 1 | $0 | 4 | Apr 6, 2023 | Director, 10%+ Owner |
ELVN | Enliven Therapeutics, Inc. | Feb 23, 2023 | 2 | $0 | 4 | Feb 27, 2023 | Director, 10%+ Owner |
ELVN | Enliven Therapeutics, Inc. | Feb 23, 2023 | 0 | $0 | 3 | Feb 27, 2023 | Director, 10%+ Owner |
VRNA | Verona Pharma plc | Dec 22, 2022 | 5 | -$136M | 4 | Dec 27, 2022 | Director |
VRNA | Verona Pharma plc | Apr 28, 2022 | 1 | $0 | 4 | Apr 29, 2022 | Director |
VRNA | Verona Pharma plc | Aug 9, 2021 | 1 | $0 | 4 | Aug 10, 2021 | Director |